Pazopanib (Votrient) Market Driver, Trends, Applications & Business Strategy Forecast 2016-2021

Global Pazopanib Market is segmented, By Geographical Region into North America, Europe, China, Japan, and Southeast Asia, India. Pazopanib (trade name Votrient) is a potent and selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumor growth and inhibits angiogenesis. It has been approved for renal cell carcinoma and soft tissue sarcoma by numerous regulatory administrations worldwide.

Pazopanib Base is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated.

Browse Full Research Report @

Pazopanib is a tyrosine kinase inhibitor (TKI). Pazopanib is presented as the hydrochloride salt, with the chemical name 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl) methylamino]-2pyrimidinyl] amino]-2-methylbenzenesulfonamide monohydrochloride in the Pazopanib Market. It has the molecular formula C21H23N7O2S•HCl and a molecular weight of 473.99. Pazopanib hydrochloride is a white to slightly yellow solid. It is very slightly soluble at pH 1 and practically insoluble above pH4 in aqueous media in the Pazopanib Market.

Pazopanib is a multitargeted tyrosine kinase inhibitor acknowledged for the dealing of patients with selective subtypes of progressive soft tissue sarcoma (STS) who have earlier conventional standard chemotherapy counting anthracyclines. Data on the effectiveness in vascular sarcomas are limited. The main impartial of this study was to investigate the activity of pazopanib in vascular sarcomas.

Request Sample Copy of this Market Research @

Concomitant use of pazopanib and simvastatin increases the risk of ALT elevations and should be undertaken with caution and close monitoring. Circumvent co-administration of pazopanib and medicines that upsurge gastric pH.1,2Contemplate short-acting antacids in place of PPIs and H2 Receptor antagonists, and distinct antacid and pazopanib treating by numerous hours.

Pazopanib is used to treat clear cell irregular renal cell carcinoma. The treatment phase continues beyond 3 months. The patient must have stable or responding disease according to the Response Evaluation Criteria in Solid Tumors (RECIST). Pazopanib Market Key Players include Pfizer, Allergan, Alnylam Pharmaceuticals, Amgen, Angstrom Pharmaceuticals, Acceleron Pharma, Biocon, Bionomics and CASI Pharmaceuticals.

This report studies Pazopanib in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer, covering
• Pfizer
• Allergan
• Alnylam Pharmaceuticals
• Amgen
• Angstrom Pharmaceuticals
• AcceleronPharma
• Biocon
• Bionomics
• CASI Pharmaceuticals
• Celgene Corporation
• Enzon Pharmaceuticals
• Five Prime Therapeutics

See More Reports of this Category by Million Insights @

About Million Insights

Million Insights, is a distributor of market research reports, published by premium publishers only. We have a comprehensive market place that will enable you to compare data points, before you make a purchase. Enabling informed buying is our motto and we strive hard to ensure that our clients get to browse through multiple samples, prior to an investment. Service flexibility & the fastest response time are two pillars, on which our business model is founded. Our market research report store, includes in-depth reports, from across various industry verticals, such as healthcare, technology, chemicals, food & beverages, consumer goods, material science & automotive.

Contact Details:

Ryan Manuel

Research Support Specialist

Office No. 302, 3rd Floor, Manikchand Galleria,

Model Colony, Shivaji Nagar, Pune, MH, 411016 India

Phone: 91-20-65300184


%d bloggers like this: